CompletedNot Applicable

Efficacy and Safety of Intralesional 5-Fluorouracil and Triamcinolone Acetonide in Keloids and Hypertrophic Scars

Nepal41 participantsStarted 2020-09-01

Plain-language summary

Pathological scars like keloids and hypertrophic scars (HTS's) cause significant aesthetic, symptomatic and psychological issues to patients. Treatment is challenging with no universally accepted "gold standard" method. Plethora of options is in practice: intralesional (IL) injections, silicon sheets, lasers, cryotherapy, radiotherapy and surgery. This study analysed the effect of combination therapy of IL 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC) in keloids and HTS's.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 16 years or more, with keloids or hypertrophic scar more than 10 mm in size Exclusion Criteria: * Signs of systemic or local infection * who underwent treatment for same scar in the past 6 months * Renal failure or liver dysfunction or bone marrow suppression

What they're measuring

Scar Height

Timeframe: 12 months

Vancouver Scar Scale (VSS) Score

Timeframe: 12 months

Patient-Reported Pain Score

Timeframe: 12 months

Patient-Reported Pruritus Score

Timeframe: 12 months

Patient-Reported Scar Appearance Score

Timeframe: 12 months

Trial details

NCT IDNCT07034482

SponsorMaharajgunj Medical Campus

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-09-01

View on ClinicalTrials.gov More Keloids trials